AMH Blood Test Helps Predict IVF Success When Combined with Age
A prediction model using only AMH levels and maternal age identified 79% of women who achieved a live birth through IVF, though it over-predicted success in many cases.
Quick Facts
What This Study Found
Among all patient characteristics examined, only two factors predicted live birth after IVF: maternal age and serum anti-Müllerian hormone (AMH) concentration. A prediction model based solely on these two variables identified live births with 79.2% sensitivity but only 44.2% specificity.
The model allowed moderate distinction between couples with good versus poor IVF prognosis. AMH, a peptide hormone produced by ovarian follicles that reflects ovarian reserve, proved to be one of the most valuable markers for predicting IVF success alongside age.
Key Numbers
79.2% sensitivity · 44.2% specificity · Only AMH + age predicted live birth · IVF cycles from 2005-2008
How They Did This
Researchers analyzed a database of first-time IVF cycles performed between 2005 and 2008 at University Hospital in Modena, Italy. They used logistic regression to test which baseline patient characteristics predicted live birth. After identifying AMH and age as the only significant predictors, they built a model using just these two variables and evaluated its sensitivity and specificity for predicting live birth outcomes.
Why This Research Matters
Predicting which women will have a successful IVF outcome is critically important for counseling, treatment planning, and managing expectations. This study confirmed that AMH — a peptide biomarker measurable with a simple blood test — adds predictive value beyond age alone. For fertility clinics, incorporating AMH into prognostic models helps identify women who may need more aggressive treatment protocols or who have particularly favorable odds.
The Bigger Picture
AMH has become one of the standard blood tests in fertility medicine, and this study was among the early validations of its predictive power for IVF outcomes. Since 2011, AMH testing has been widely adopted worldwide, and more sophisticated prediction models incorporating additional variables have been developed. The core finding — that AMH and age are the two dominant predictors of IVF success — has been confirmed repeatedly.
What This Study Doesn't Tell Us
The model had low specificity (44.2%), meaning it frequently predicted success for women who didn't achieve a live birth. Data came from a single center in Italy from 2005-2008, and IVF techniques have improved since. The abstract doesn't report the total number of cycles analyzed. The model only uses pre-treatment factors and doesn't account for embryo quality or other cycle-specific variables.
Questions This Raises
- ?Can adding embryo quality or other cycle-specific factors significantly improve prediction beyond AMH and age alone?
- ?Does this model perform equally well across different ethnic populations and IVF protocols?
- ?At what AMH threshold should clinicians counsel patients about reduced IVF success probability?
Trust & Context
- Key Stat:
- 79.2% sensitivity The AMH + age model correctly identified nearly 4 out of 5 women who achieved a live birth through IVF
- Evidence Grade:
- This is a moderate-grade prognostic study based on retrospective analysis of a clinical database from a single center. While the statistical approach is sound, the low specificity and single-center design limit generalizability.
- Study Age:
- Published in 2011, this is an older study from a period when AMH testing was still being validated for clinical use. AMH has since become a standard fertility biomarker, and more refined prediction models are now available.
- Original Title:
- Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.
- Published In:
- Reproductive biomedicine online, 22(4), 341-9 (2011)
- Authors:
- La Marca, A, Nelson, S M, Sighinolfi, G, Manno, M, Baraldi, E, Roli, L, Xella, S, Marsella, T, Tagliasacchi, D, D'Amico, R, Volpe, A
- Database ID:
- RPEP-01797
Evidence Hierarchy
Frequently Asked Questions
What is AMH and why does it predict IVF success?
Anti-Müllerian hormone (AMH) is a peptide produced by small follicles in the ovaries. Higher AMH levels indicate a larger pool of remaining eggs (ovarian reserve). Women with more eggs available tend to respond better to IVF stimulation, producing more embryos and having better chances of a live birth.
Why was the model's specificity so low (44.2%)?
Low specificity means the model often predicted success for women who didn't achieve a live birth. This happens because IVF success depends on many factors beyond ovarian reserve — including sperm quality, uterine factors, embryo genetics, and lab conditions — that a simple two-variable model can't capture.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01797APA
La Marca, A; Nelson, S M; Sighinolfi, G; Manno, M; Baraldi, E; Roli, L; Xella, S; Marsella, T; Tagliasacchi, D; D'Amico, R; Volpe, A. (2011). Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.. Reproductive biomedicine online, 22(4), 341-9. https://doi.org/10.1016/j.rbmo.2010.11.005
MLA
La Marca, A, et al. "Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.." Reproductive biomedicine online, 2011. https://doi.org/10.1016/j.rbmo.2010.11.005
RethinkPeptides
RethinkPeptides Research Database. "Anti-Müllerian hormone-based prediction model for a live bir..." RPEP-01797. Retrieved from https://rethinkpeptides.com/research/la-2011-antimllerian-hormonebased-prediction-model
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.